Devyser Diagnostics (DVYSR.ST) Stock Analysis & AI Equity Report
Devyser Diagnostics (DVYSR.ST) overview
Devyser Diagnostics (DVYSR.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Devyser Diagnostics reported revenue of SEK 251m and operating profit of SEK 10.6m; the year-end share price was 114.20 SEK and market capitalisation was SEK 1,895m. Devyser Diagnostics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Devyser Diagnostics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Devyser Diagnostics
Devyser Diagnostics develops, manufactures and sells diagnostic kits and analysis services for complex DNA testing. Its products support clinical laboratories in hereditary disease, oncology, transplantation and other genetic testing areas, helping with targeted cancer therapy, diagnosis and post-transplant monitoring. The company also offers software and laboratory services that simplify workflows and improve testing throughput.
Generate the Devyser Diagnostics report
Devyser Diagnostics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Devyser Diagnostics and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Devyser Diagnostics
Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.